Logo image of WAVE.CA

WAVERLEY PHARMA INC (WAVE.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:WAVE - CA94357L1058 - Common Stock

0.02 CAD
+0.01 (+33.33%)
Last: 12/22/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to WAVE. WAVE was compared to 23 industry peers in the Biotechnology industry. Both the profitability and financial health of WAVE have multiple concerns. WAVE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

WAVE had negative earnings in the past year.
In the past year WAVE has reported a negative cash flow from operations.
WAVE had negative earnings in each of the past 5 years.
In the past 5 years WAVE always reported negative operating cash flow.
WAVE.CA Yearly Net Income VS EBIT VS OCF VS FCFWAVE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -500K -1M -1.5M -2M

1.2 Ratios

The Return On Assets of WAVE (-28.81%) is better than 69.57% of its industry peers.
Industry RankSector Rank
ROA -28.81%
ROE N/A
ROIC N/A
ROA(3y)-101.52%
ROA(5y)-69.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WAVE.CA Yearly ROA, ROE, ROICWAVE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

With a decent Gross Margin value of 39.48%, WAVE is doing good in the industry, outperforming 73.91% of the companies in the same industry.
In the last couple of years the Gross Margin of WAVE has grown nicely.
WAVE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.45%
GM growth 5Y60.51%
WAVE.CA Yearly Profit, Operating, Gross MarginsWAVE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

WAVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for WAVE remains at a similar level compared to 1 year ago.
WAVE has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for WAVE has been reduced compared to a year ago.
WAVE.CA Yearly Shares OutstandingWAVE.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
WAVE.CA Yearly Total Debt VS Total AssetsWAVE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -13.42, we must say that WAVE is in the distress zone and has some risk of bankruptcy.
WAVE has a Altman-Z score (-13.42) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.42
ROIC/WACCN/A
WACC7.94%
WAVE.CA Yearly LT Debt VS Equity VS FCFWAVE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 0.11 indicates that WAVE may have some problems paying its short term obligations.
The Current ratio of WAVE (0.11) is worse than 60.87% of its industry peers.
WAVE has a Quick Ratio of 0.11. This is a bad value and indicates that WAVE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.04, WAVE is not doing good in the industry: 69.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.04
WAVE.CA Yearly Current Assets VS Current LiabilitesWAVE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

WAVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.45%, which is quite impressive.
Looking at the last year, WAVE shows a very strong growth in Revenue. The Revenue has grown by 2017.58%.
WAVE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.30% yearly.
EPS 1Y (TTM)83.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
Revenue 1Y (TTM)2017.58%
Revenue growth 3Y-35.27%
Revenue growth 5Y-16.3%
Sales Q2Q%1130.8%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WAVE.CA Yearly Revenue VS EstimatesWAVE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WAVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WAVE.CA Price Earnings VS Forward Price EarningsWAVE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WAVE.CA Per share dataWAVE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

WAVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

WAVERLEY PHARMA INC

TSX-V:WAVE (12/22/2025, 7:00:00 PM)

0.02

+0.01 (+33.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-25 2025-11-25
Earnings (Next)04-27 2026-04-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners74.9%
Ins Owner ChangeN/A
Market Cap1.08M
Revenue(TTM)1.51M
Net Income(TTM)-367.10K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.03
BVpS-0.04
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.48%
FCFM N/A
ROA(3y)-101.52%
ROA(5y)-69.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.45%
GM growth 5Y60.51%
F-Score3
Asset Turnover1.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.04
Altman-Z -13.42
F-Score3
WACC7.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2017.58%
Revenue growth 3Y-35.27%
Revenue growth 5Y-16.3%
Sales Q2Q%1130.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y74.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.35%
OCF growth 3YN/A
OCF growth 5YN/A

WAVERLEY PHARMA INC / WAVE.CA FAQ

What is the ChartMill fundamental rating of WAVERLEY PHARMA INC (WAVE.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA.


Can you provide the valuation status for WAVERLEY PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to WAVERLEY PHARMA INC (WAVE.CA). This can be considered as Overvalued.


Can you provide the profitability details for WAVERLEY PHARMA INC?

WAVERLEY PHARMA INC (WAVE.CA) has a profitability rating of 2 / 10.


What is the financial health of WAVERLEY PHARMA INC (WAVE.CA) stock?

The financial health rating of WAVERLEY PHARMA INC (WAVE.CA) is 1 / 10.